Innoviva (NASDAQ:INVA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research note issued on Monday,Benzinga reports. They presently have a $42.00 price objective on the biotechnology company’s stock. BTIG Research’s price target suggests a potential upside of 85.27% from the stock’s previous close. Several […]

Novavax (NASDAQ:NVAX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $19.00 price objective on the biopharmaceutical company’s stock. BTIG Research’s price objective points to a potential upside of 110.41% from the stock’s current price. NVAX has […]